Solaris Resources Inc. (SLSR)

SELLAS Life Sciences Group Inc. surged as promising clinical news boosted investor optimism; stocks have been trading up by 14.72 percent. Key Takeaways For SLS Traders Q1 loss came in at $0.05 per share, beating the $0.06 Street view and improving from a $0.07 loss last year.

SELLAS Life Sciences Group Inc. stocks have been trading down by -12.54 percent following negative sentiment over its latest clinical developments. Key Takeaways SLS has run from the mid-$4s to the high-$8s in May 2026, with the latest daily candle showing a sharp pullback and elevated volatility.

Following the last earnings report on Nov 12, 2025, SLSR's stock price moved — from — to —.

SELLAS Life Sciences Group Inc. jumped as stocks have been trading up by 13.7 percent on promising clinical trial progress Key Takeaways Q1 loss of $0.05 per share at SELLAS Life Sciences came in better than the $0.06 loss Wall Street expected. The Q1 loss also narrowed from $0.07 per share ...

Looking to buy Solaris Resources Inc Stock? Get the latest SLSR quote, news, earnings, forecast, price targets, and market insights. Start investing on Public.com.